Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Por Vogl, Ursula M., Andalibi, Haleh, Klaus, Alexander, Vormittag, Laurenz, Schima, Wolfgang, Heinrich, Bettina, Kafka, Alice, Winkler, Thomas, Öhler, Leopold
Publicado no BMC Cancer (2019)

Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

Por Vogl, Ursula M, Bojic, Marija, Lamm, Wolfgang, Frischer, Josa M, Pichelmayer, Oskar, Kramer, Gero, Haitel, Andrea, Kitz, Klaus, Harmankaya, Kaan, Zielinski, Christoph C, Schmidinger, Manuela
Publicado em 2010

Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres

Por Vogl, Ursula M., Vormittag, Laurenz, Winkler, Thomas, Kafka, Alice, Weiser-Jasch, Olivia, Heinrich, Bettina, Roider-Schur, Sophie, Andalibi, Haleh, Autzinger, Eva, Schima, Wolfgang, Klaus, Alexander, Zacherl, Johannes, Wimberger, Günter Michael, Öhler, Leopold
Publicado no J Gastrointest Oncol (2020)